HB
Hetal Bhupatrai Mehta
About Hetal Bhupatrai Mehta
Data last updated:
Hetal Bhupatrai Mehta is a Director at Unnati Pharmaceuticals Private Limited (since 2010). The companies operate in Chemicals and Pharma. Unnati Pharmaceuticals Private Limited reported revenue of ₹155 Cr (FY 2023). Earlier, Hetal Bhupatrai Mehta was a Director at Pragati Raw Pharma Private Limited (1999–2010).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 30 Jun 2010 | 2003 | ₹155 Cr (FY 2023) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 17 Jun 1999 | 1999 | ₹89.58 Cr (FY 2025) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Hetal Bhupatrai Mehta
| Name | DIN | Company | Designation |
|---|---|---|---|
| Naishil Hetal Mehta | 07686570 | Unnati Pharmaceuticals Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Hetal Bhupatrai Mehta
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hetal Bhupatrai Mehta
Hetal Bhupatrai Mehta currently holds 1 directorship: Unnati Pharmaceuticals Private Limited (Director, since 30 Jun 2010, revenue ₹155 Cr (FY 2023)).
Hetal Bhupatrai Mehta was first appointed on 17 Jun 1999 as Director at Pragati Raw Pharma Private Limited. The most recent appointment on record is 30 Jun 2010 at Unnati Pharmaceuticals Private Limited.
Hetal Bhupatrai Mehta held 1 earlier board appointment: Pragati Raw Pharma Private Limited (Director, 17 Jun 1999 to 15 Jul 2010).
The current boards of Hetal Bhupatrai Mehta's companies include Naishil Hetal Mehta (Unnati Pharmaceuticals Private Limited).